With an eye on the FDA, Lexicon and Sanofi line up more positive data on diabetes drug
Lexicon Pharmaceuticals $LXRX is beefing up the positive data it’s been accumulating for the SGLT1/SGLT2 inhibitor sotagliflozin as it preps applications for Type 1 diabetes.
The inTandem2 study already demonstrated again that the drug significantly cut A1C in 24 weeks, and researchers can now point to fresh data underlining how that effect is sustained through the first full year of treatment. This study hit the primary and all secondary endpoints, including reduced weight and blood pressure. And it’s three for three in Phase III.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.